S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CRBU · Caribou Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Caribou Biosciences Inc (CRBU)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.54
+0.02
(+4.04%)
● At close: October 21 at 4:00:00 PM EDT
$0.62
+0.07
(+13.13%)
Overnight:
8:36:56 PM EDT
DAY'S RANGE
$0.54
$0.52
$0.55
52-WEEK RANGE
$0.54
$0.44
$3.54
What's happening
- CRBU is up 4.04% today, trading at $0.54. — Live quote
- Volume today (44,612) is well below its 3-month average of 2,472,340. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.24 actual vs. $-0.32 estimated (+25.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CRBU
-67.36%
vs S&P 500
-80.14%
1-YEAR RETURN
CRBU
-81.60%
vs S&P 500
-96.16%
6-MONTH RETURN
CRBU
-75.86%
3-MONTH RETURN
CRBU
-68.55%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.24
Est. $-0.32
BEAT +25.7%
2026-04-26 (Q1 2026)
$-0.26
Est. $-0.32
BEAT +19.8%
2026-01-26 (Q4 2025)
$-0.28
Est. $-0.32
BEAT +11.4%
2025-10-26 (Q3 2025)
$-0.30
Est. $-0.37
BEAT +18.4%
Valuation Measures & Ratios
Enterprise Value4$29.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)5.54
Price / Book71.78
EV4 / Revenue2.93
EV4 / EBITDA—
Profit Margin-1030.42%
Operating Margin-1090.90%
Return on Equity (ROE8)-89.11%
Return on Assets (ROA9)-62.47%
Avg Volume (3M)2,472,340
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $177.1M | $183.3M | $214.0M | $117.5M | $86.7M |
| P/E | -1.35 | -1.25 | -1.37 | -0.71 | -0.56 |
| Price/Sales | 20.21 | 19.07 | 23.15 | 11.18 | 8.44 |
| Price/Book | 1.80 | 1.80 | 1.51 | 0.71 | 0.40 |
| EV/Revenue | 17.22 | 17.81 | 21.94 | 8.79 | 5.58 |
| EV/EBITDA | -1.20 | -1.20 | -1.32 | — | — |
| ROE | -133.55% | -143.82% | -110.21% | -100.20% | -70.71% |
| ROA | -91.76% | -98.47% | -80.17% | -75.36% | -56.13% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short12,914,422
Change from Prior Settlement-0.49%
% of Float—
Days to Cover (Short Ratio)13.09
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -43.8% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -1030.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -81.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CRBU
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $2.4M | $2.2M | $2.7M | $2.4M | $2.0M | $3.5M | $2.4M |
| Operating income | -$25.3M | -$26.3M | -$29.4M | -$47.6M | -$42.9M | -$38.2M | -$43.5M | -$46.0M |
| Net income | -$24.3M | -$25.1M | -$27.5M | -$54.1M | -$40.0M | -$34.7M | -$37.7M | -$41.2M |
| EPS (diluted) | $-0.24 | $-0.26 | $-0.30 | $-0.58 | $-0.43 | $-0.38 | $-0.42 | $-0.46 |
| EPS (basic) | $-0.24 | $-0.26 | $-0.30 | $-0.58 | $-0.43 | $-0.38 | $-0.42 | $-0.46 |
| Operating margin | -$1.7K | -$1.1K | -$1.3K | -$1.8K | -$1.8K | -$1.9K | -$1.3K | -$1.9K |
| Net margin | -$1.6K | -$1.0K | -$1.3K | -$2.0K | -$1.7K | -$1.7K | -$1.1K | -$1.7K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $142.8M | $149.0M | $175.4M | $195.0M | $220.9M | $273.7M | $313.3M | $344.3M |
| Total liabilities | $44.7M | $47.0M | $53.2M | $53.1M | $54.8M | $56.4M | $60.4M | $63.1M |
| Stockholders' equity | $98.1M | $102.0M | $122.2M | $141.8M | $166.1M | $217.2M | $253.0M | $281.2M |
| Total current assets | $116.6M | $122.4M | $145.2M | $155.5M | $192.5M | $217.3M | $219.4M | $237.4M |
| Total current liabilities | $18.0M | $19.7M | $25.4M | $28.1M | $28.9M | $28.5M | $30.7M | $32.2M |
| Cash & equivalents | $26.2M | $12.1M | $12.4M | $11.1M | $25.2M | $29.4M | $16.3M | $32.0M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $203.0K | $227.0K | $69.0K | $242.0K | $71.0K | $88.0K | $265.0K | $184.0K |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $5.5M | $6.1M | $6.8M | $7.6M | $8.2M | $18.5M | $19.3M | $19.6M |
| Other non-current assets | $2.1M | $2.1M | $2.2M | $3.8M | $3.6M | $5.0M | $5.5M | $4.7M |
| Accounts payable | $3.1M | $3.5M | $5.8M | $3.8M | $3.2M | $3.9M | $2.5M | $2.7M |
| Accrued liabilities | $13.1M | $13.9M | $16.5M | $19.4M | $20.5M | $19.9M | $23.6M | $25.4M |
| Deferred revenue (current) | $372.0K | $994.0K | $1.9M | $2.2M | $2.8M | $2.8M | $3.1M | $2.8M |
| Other current liabilities | $1.7M | $732.0K | $2.7M | $1.9M | $2.1M | $1.5M | $1.7M | $973.0K |
| Common stock & paid-in capital | $11.0K | $10.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K |
| Retained earnings | -$645.9M | -$621.6M | -$596.5M | -$570.0M | -$542.5M | -$488.4M | -$448.4M | -$412.9M |
| Accumulated other comprehensive income (loss) | -$71.0K | -$23.0K | $103.0K | $93.0K | $40.0K | $167.0K | $255.0K | $789.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.8M | -$27.0M | -$20.8M | -$25.2M | -$28.3M | -$36.7M | -$35.5M | -$32.7M |
| Investing cash flow | $18.9M | $24.0M | $18.0M | $10.9M | $24.0M | $49.4M | $15.9M | $26.5M |
| Financing cash flow | $17.9M | $2.7M | $4.1M | $277.0K | $6.0K | $468.0K | $3.9M | $244.0K |
| Free cash flow | -$22.8M | -$27.1M | -$20.6M | -$25.3M | -$28.7M | -$37.8M | -$36.0M | -$33.3M |
| Capital expenditures | $1.0K | $72.0K | -$216.0K | $115.0K | $418.0K | $1.0M | $518.0K | $673.0K |
| Depreciation & amortization | $625.0K | $649.0K | $682.0K | $631.0K | $1.2M | $1.2M | $1.2M | $1.2M |
| Share-based compensation | $2.5M | $2.4M | $2.7M | $2.9M | $3.1M | $3.9M | $3.9M | $4.1M |
| Deferred income taxes | — | — | -$551.0K | — | — | — | -$10.0K | — |
| Change in accounts receivable | -$24.0K | $158.0K | -$173.0K | $171.0K | -$17.0K | -$177.0K | $81.0K | -$32.0K |
| Change in accounts payable | -$423.0K | -$2.2M | $1.9M | $561.0K | -$630.0K | $1.4M | -$229.0K | -$477.0K |
| Purchases of investments | $20.5M | $22.1M | $44.0M | $57.4M | $32.2M | $15.5M | $55.5M | $93.5M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M |
| Net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M | -$66.9M |
| EPS (diluted) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 |
| EPS (basic) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 |
| Operating margin | -$1.3K | -$1.7K | -$337 | -$768 | -$698 |
| Net margin | -$1.3K | -$1.5K | -$296 | -$718 | -$697 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 |
|---|---|---|---|---|---|
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | — |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | — |
| Stockholders' equity | $122.2M | $253.0M | $368.4M | $300.9M | — |
| Total current assets | $145.2M | $219.4M | $338.8M | $260.2M | — |
| Total current liabilities | $25.4M | $30.7M | $28.3M | $28.1M | — |
| Cash & equivalents | $12.4M | $16.3M | $51.2M | $58.3M | — |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $69.0K | $265.0K | $148.0K | $202.0K | — |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $6.8M | $19.3M | $18.3M | $10.7M | — |
| Other non-current assets | $2.2M | $5.5M | $1.6M | $1.5M | — |
| Accounts payable | $5.8M | $2.5M | $3.1M | $1.1M | — |
| Accrued liabilities | $16.5M | $23.6M | $21.1M | $16.1M | $13.1M |
| Deferred revenue (current) | $1.9M | $3.1M | $2.8M | $9.9M | — |
| Other current liabilities | $816.0K | $1.7M | $1.1M | $1.4M | — |
| Common stock & paid-in capital | $9.0K | $9.0K | $8.0K | $6.0K | — |
| Retained earnings | -$596.5M | -$448.4M | -$299.3M | -$197.2M | — |
| Accumulated other comprehensive income (loss) | $103.0K | $255.0K | $30.0K | -$1.5M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$111.0M | -$138.2M | -$93.3M | -$91.0M | -$32.5M |
| Investing cash flow | $102.2M | $86.6M | -$68.2M | -$93.2M | -$176.4M |
| Financing cash flow | $4.8M | $16.7M | $154.3M | $2.1M | $433.4M |
| Free cash flow | -$112.4M | -$143.1M | -$104.9M | -$97.4M | -$34.6M |
| Capital expenditures | $1.4M | $4.9M | $11.6M | $6.5M | $2.1M |
| Depreciation & amortization | $3.6M | $3.9M | $3.5M | $1.6M | $984.0K |
| Share-based compensation | $12.7M | $16.7M | $13.8M | $11.7M | $3.4M |
| Deferred income taxes | -$551.0K | -$10.0K | $178.0K | -$95.0K | $320.0K |
| Change in accounts receivable | -$196.0K | $117.0K | -$54.0K | -$951.0K | $1.0M |
| Change in accounts payable | $3.3M | -$354.0K | $1.8M | -$2.7M | $1.1M |
| Purchases of investments | $149.2M | $304.4M | $394.8M | $339.1M | $173.3M |
| Sales/maturities of investments | — | — | — | $252.9M | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CRBU as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-20 to 2026-02-25
Recent transactions
- Most recent: Kelly Timothy P (Chief Technology Officer) — Open market sale of 6,228 shares on 2026-02-25.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kelly Timothy P | Chief Technology Officer | Open market sale | 2026-02-25 | 6,228 |
| MCCLUNG BARBARA G | Chief Legal Officer | Open market sale | 2026-02-24 | 6,938 |
| Khan Ruhi Ahmad | Chief Business Officer | Open market sale | 2026-02-24 | 6,938 |
| Albertson Tina M. | Chief Medical Officer | Open market sale | 2026-02-24 | 1,066 |
| Ryali Sriram | Chief Financial Officer | Grant / award | 2026-02-20 | 55,000 |
| Haurwitz Rachel E. | President and CEO | Grant / award | 2026-02-20 | 151,700 |
| Kanner Steven | Chief Scientific Officer | Open market sale | 2025-02-21 | 3,564 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P | Chief Technology Officer | Open market sale | 6,228 | $1.93 |
| 2026-02-24 | Kelly Timothy P | Chief Technology Officer | Open market sale | 3,147 | $1.96 |
| 2026-02-24 | MCCLUNG BARBARA G | Chief Legal Officer | Open market sale | 6,938 | $1.96 |
| 2026-02-24 | Khan Ruhi Ahmad | Chief Business Officer | Open market sale | 6,938 | $1.96 |
| 2026-02-24 | Albertson Tina M. | Chief Medical Officer | Open market sale | 1,066 | $1.96 |
| 2026-02-20 | Kelly Timothy P | Chief Technology Officer | Grant / award | 45,000 | $0.00 |
| 2026-02-20 | MCCLUNG BARBARA G | Chief Legal Officer | Grant / award | 45,000 | $0.00 |
| 2026-02-20 | Khan Ruhi Ahmad | Chief Business Officer | Grant / award | 45,000 | $0.00 |
| 2026-02-20 | Albertson Tina M. | Chief Medical Officer | Grant / award | 55,000 | $0.00 |
| 2026-02-20 | Ryali Sriram | Chief Financial Officer | Grant / award | 55,000 | $0.00 |
| 2026-02-20 | Haurwitz Rachel E. | President and CEO | Grant / award | 151,700 | $0.00 |
| 2025-03-14 | Haurwitz Rachel E. | President and CEO | Open market purchase | 20,000 | $1.02 |
| 2025-02-21 | MCCLUNG BARBARA G | Chief Legal Officer | Open market sale | 3,564 | $1.35 |
| 2025-02-21 | Khan Ruhi Ahmad | Chief Business Officer | Open market sale | 3,564 | $1.35 |
| 2025-02-21 | Kanner Steven | Chief Scientific Officer | Open market sale | 3,564 | $1.35 |
| 2025-02-20 | Haurwitz Rachel E. | President and CEO | Grant / award | 136,750 | $0.00 |
| 2025-02-20 | Albertson Tina M. | Chief Medical Officer | Grant / award | 14,589 | $0.00 |
| 2025-02-20 | MCCLUNG BARBARA G | Chief Legal Officer | Grant / award | 37,500 | $0.00 |
| 2025-02-20 | Khan Ruhi Ahmad | Chief Business Officer | Grant / award | 37,500 | $0.00 |
| 2025-02-20 | Kelly Timothy P | Chief Technology Officer | Grant / award | 37,500 | $0.00 |
| 2025-02-20 | Kanner Steven | Chief Scientific Officer | Grant / award | 37,500 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:07 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 8-K | 2026-10-02 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-17 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-07 | 8-K | 2026-05-07 | View on SEC.gov → |
| 2026-03-31 | 8-K | 2026-03-31 | View on SEC.gov → |
| 2026-03-05 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-05 | 8-K | 2026-03-05 | View on SEC.gov → |
| 2026-02-27 | 4 | 2026-02-25 | View on SEC.gov → |
| 2026-02-24 | 4 | 2026-02-20 | View on SEC.gov → |
Recent news
Headlines about CRBU (Caribou Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Caribou Biosciences reviews options. Caribou Biosciences stock is valued at USD 55.6 million
AD HOC NEWS · 2026-10-21 -
CRBU261120P00001500 interactive stock chart | CRBU Nov 2026 1.500 put stock
Yahoo Finance UK · 2026-10-18 -
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Benzinga · 2026-10-09 -
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Benzinga · 2026-10-09 -
In the hunt for reverse merger targets, Caribou could be prized game
Yahoo · 2026-10-08 -
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 2026-10-08 -
This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Benzinga · 2026-10-08 -
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Benzinga · 2026-10-08
No headlines in this category right now — try “All”.